肺癌性淋巴管炎的研究进展  

Research progress of pulmonary lymphangitic carcinomatosis

作　　者：赵丽丽 赵文文[1] 赵文飞 冯青青 阮岱玮 魏红梅[1] ZHAO Lili;ZHAO Wenwen;ZHAO Wenfei;FENG Qingqing;RUAN Daiwei;WEI Hongmei(Second Department of General Oncology,Affiliated Qingdao Central Hospital,Qingdao University ,Qingdao 266042,China)

机构地区：[1]青岛大学附属青岛市中心医院肿瘤综合二科,山东青岛266042 [2]University of Glasgow,Scotland,G128QQ

出　　处：《临床肿瘤学杂志》2021年第10期955-958,共4页Chinese Clinical Oncology

摘　　要：肺癌性淋巴管炎(PLC)是一种特殊形式的肺转移癌,起病迅速且病情进展快,常合并有肺动脉高压及血栓性微血管病(PTTM),预后差。随着研究的深入,证实血管内皮细胞生长因子(VEGF)在肺癌性淋巴管炎的发生、发展中发挥关键作用,尤以VEGF-C为著。目前对该病的认识仍处于探索阶段,针对原发肿瘤的治疗仍是首选的治疗方法,随着精准医学的发展,抗血管生成药物及表皮细胞生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)等相关靶向药物治疗肺癌性淋巴管炎已在部分个案报道中初显成效。Pulmonary lymphangitic carcinomatosis(PLC)is a special form of lung metastatic cancer with rapid onset and rapid progress.It is often associated with pulmonary hypertension and thrombotic microangiopathy(PTTM),and the prognosis ispoor.With the progress of research,it is confirmed that vascular endothelial growth factor(VEGF)plays an important role in the occurrence and development of PLC,especially VEGF-C.At present,theunderstanding of the disease is still in the exploratory stage,and the treatment for primary tumoris still the first choice.With the development ofprecision medicine,anti-angiogenic drugs and epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs)and other related targeted drugs have achieved initial results in some case reports of PLC.

关 键 词：肺癌性淋巴管炎(PLC) 血管内皮生长因子(VEGF) 

分 类 号：R734.2[医药卫生—肿瘤]